A5022617651- Diabetes Management and Research
- Diabetes Treatment and Management
- Lymphoma Diagnosis and Treatment
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Chronic Lymphocytic Leukemia Research
- Metabolism, Diabetes, and Cancer
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Receptor Mechanisms and Signaling
- Diabetes, Cardiovascular Risks, and Lipoproteins
- T-cell and Retrovirus Studies
- Chemokine receptors and signaling
- Cardiovascular Syncope and Autonomic Disorders
- Heart Rate Variability and Autonomic Control
- Semantic Web and Ontologies
- Adrenal Hormones and Disorders
- Antioxidant Activity and Oxidative Stress
- Circadian rhythm and melatonin
- Hepatitis B Virus Studies
- Vitamin K Research Studies
- Viral-associated cancers and disorders
- Genetic factors in colorectal cancer
Thomas Jefferson University
2023-2024
University Hospital of Bern
2024
Sidney Kimmel Cancer Center
2023-2024
IFOM
2023
Azienda Ospedaliera di Perugia
2018-2019
University of Bari Aldo Moro
2018-2019
University of Perugia
1994-2005
OBJECTIVE: To establish whether the short-acting insulin analog lispro can be successfully implemented in long-term intensive therapy type 1 diabetes, and if so, what its effects are on glycemic control frequency awareness of hypoglycemia. RESEARCH DESIGN AND METHODS: We randomized 56 diabetic patients to treatment with either (n = 28) or human regular (Hum-R; n as mealtime for year (open design, parallel groups). Lispro was injected at Hum-R given 10-40 min before meals (bedtime NPH...
To determine the contribution of clinically overt diabetic autonomic neuropathy (DAN) to reduced plasma adrenaline responses hypoglycemia in IDDM and establish its selectivity for hypoglycemia, we studied 17 patients (7 without DAN [DAN−] 10 with [DAN+]), whom 5 had did not have postural hypotension (DAN+PH+ DAN+PH−, respectively), 8 nondiabetic subjects on 2 different occasions, i.e., clamped (steps from 5.0 2.2 mmol/l glucose) 30-min steady-state exercise at 55% VO2max. Recent antecedent...
OBJECTIVE: To quantitate the contribution of postprandial blood glucose, which improves with short-acting insulin analog lispro [Lys(B28),Pro(B29)] in type 1 diabetes, to overall 24-h glucose concentration and long-term HbA1c under conditions different postabsorptive glucose. RESEARCH DESIGN AND METHODS: A total 24 diabetic patients on intensive therapy premeal human regular (Hum-R) bedtime NPH were randomly assigned a continuation Hum-R (group 1, n = 8), 2, or + (in variable proportions)...
To establish whether lispro may be a suitable short-acting insulin preparation for meals in intensive treatment of Type 1 diabetes mellitus (DM) patients already chronic good glycaemic control with conventional insulins, 69 on therapy (4 daily s.c. injections, soluble at each meal, NPH bedtime, HbA1c <7.5 %) were studied an open, cross-over design two periods 3 months (lispro or soluble). The % and frequency hypoglycaemia assessed under four different conditions (Groups I–IV). Lispro was...
OBJECTIVE To compare postprandial metabolic control after subcutaneous injection of a short-acting insulin analog [Lys(B289),Pro(B29)] (Lispro) or human regular (Humulin R U-100 [Hum-R]) in insulin-dependent diabetes mellitus (IDDM) short duration with residual β-cell function. RESEARCH DESIGN AND METHODS Six IDDM patients (age 25 ± 2 years, 14 months, HbA1c 6.4 0.5%) pancreatic function (fasting plasma C-peptide 0.19 0.02 nmol/l) were studied on three different occasions. Postbreakfast...
Abstract Dysregulated nuclear-cytoplasmic trafficking has been shown to play a role in oncogenesis several types of solid tumors and hematological malignancies. Exportin 1 (XPO1) is responsible for the nuclear export proteins RNA species, mainly tumor suppressors. KPT-330, small molecule inhibitor XPO1, approved treating relapsed multiple myeloma diffuse large B-cell lymphoma. Cutaneous T-cell lymphoma (CTCL) an extranodal non-Hodgkin with adverse prognosis limited treatment options advanced...
To assess the mechanisms of fasting hyperglycemia in NIDDM patients with mild elevation plasma glucose (FPG) compared overt hyperglycemia, we studied 29 NIDDM, who were divided two groups according to their (<7.8 and > or =7.8 mmol/l for A B, respectively), 16 control subjects matched age, sex, body mass index. All infused [3-3H]glucose between 10:00 P.M. A.M. during overnight determine fluxes. In 27 (17 diabetic 10 control), [U-14C]alanine was simultaneously 4:00 measure gluconeogenesis...
OBJECTIVE To establish the effects of short-acting insulin analog Lispro versus human regular (Hum-R) on postprandial metabolic control in IDDM. RESEARCH DESIGN AND METHODS Four studies were performed 10 C-peptide-negative IDDM patients. or Hum-R (0.15 U/kg) + NPH (0.07 injected subcutaneously 30 min 5 (Lispro) before lunch. Preprandial plasma glucose (PG) was maintained all four occasions at ∼ 7.3 mmol/l by intravenous insulin. RESULTS After subcutaneous injection, free (FIRI) greater...
To complement results of the SUSTAIN program, this study assessed effectiveness and safety once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care.This was a multicenter, observational, retrospective including all patients treated semaglutide. Changes clinical outcomes from baseline to 6 12 months were who glucagon-like peptide receptor agonist (GLP-1RA) naïve or switching another GLP-1RA. Discontinuation rate assessed.Overall, 216 (mean age 64...
Efficacy and safety of the fixed ratio combination insulin degludec liraglutide (IDegLira) has been largely documented. However, long-term data are limited. This study aimed at describing persistence in therapy effectiveness 48 months IDegLira. We conducted an observational based on retrospective chart review. All patients treated with IDegLira during 2018–2022 were included. Data treatment approaches clinical outcomes collected first prescription (T0) after 6, 12, 24, 36, months. Overall,...
Objective. To evaluate the contribution of MHC class I chain-related A (MICA) gene polymorphism to genetic risk systemic lupus erythematosus (SLE).
To test the hypothesis that hypoglycemia unawareness and impaired counterregulation are reversible after meticulous prevention of in IDDM patients with diabetic autonomic neuropathy (DAN), 21 (8 without DAN [DAN−]; 13 [DAN+]; latter, 7 had orthostatic hypotension [DAN+PH+] 6 did not [DAN+PH−]) 15 nondiabetic subjects were studied during stepped (plateau plasma glucose decrements from 5.0 to 2.2 mmol/l) before months (intensive therapy). After months, frequency mild decreased ∼20 ∼2...
Hodgkin's lymphoma (HL) is now a highly curable disease, with an improving 5-year survival rate that has reached 86%. At the time of presentation, HL usually almost entirely confined to lymph nodes. We performed retrospective single-institution study 384 cases median follow-up 44 months, aim identifying clinical and radiological characteristics outcomes patients bone HL; 32 (8%) had primary involvement, always concurrent nodal disease. These included 22 men (69%) 10 women (31%) age as 41...
Abstract A condition of oxidative stress is known to occur in ischemic stroke, the current therapeutic intervention which largely limited thrombolysis. To assess effect vitamin C ‐ conjunction aspirin stroke‐related lipid peroxidation, we measured plasma levels ascorbate, 8,12‐isoprostanes F 2α ‐VI (8,12‐iPF ‐VI) and activities a broad spectrum antioxidant enzymes micronutrients stroke patients randomized receive, from onset up three months, either (200 mg/day) plus (300 or only mg/day). By...
Real-world evidence on effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. The aim the study was to evaluate patterns use long-term IDeg routine clinical practice. This an observational longitudinal study. A retrospective chart review all type 2 treated performed temporal trends outcomes were assessed. All data stratified by treatment modality: switch group consisted already another basal before initiating IDeg; add-on insulin-naïve patients. Overall,...
An improvement of type 2 diabetes treatment is represented by the recent availability a fixed-ratio combination slow insulin degludec and GLP-1 RA liraglutide (IDegLira), which shows encouraging clinical trial results. This work represents real-world evidence study to evaluate if obtained results are also confirmed in practice, an Italian patients' population.This retrospective observational was conducted Diabetology Service Umbria local sanitary agency (USL 1) Perugia. The investigated all...